Cell-Free DNA Methylation Predicts Chemo Benefit in Bladder Cancer
Methylation patterns in cfDNA from blood samples can help predict which patients with a type of bladder cancer may benefit from chemotherapy.
Methylation patterns in cfDNA from blood samples can help predict which patients with a type of bladder cancer may benefit from chemotherapy.
Learn how CLP's editor discovered firsthand how clinical laboratories and laboratorians are being taken for granted.
Genetic testing of the siblings of newborns with cancer genes could reduce rare pediatric cancer deaths by about 50%, an NIH-funded analysis suggests.
Cells undergo long-term changes after viral infection, pointing to why hepatitis C patients are susceptible to liver cancer.
Read MoreSiemens Healthineers’ Enhanced Liver Fibrosis (ELF) Test was granted marketing authorization under the De Novo review pathway.
Read MoreExact Sciences Corp. announced that the performance of its Oncoguard Liver liquid biopsy test is...
Read MoreA meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited TGCT.
Read MoreADXBLADDER, a urinary biomarker test for bladder cancer, is currently undergoing clinical trials in the U.S.
Read MoreThe FDA awarded AnchorDx a Breakthrough Device Designation for UriFind, an early detection test for bladder cancer based on urine DNA methylation detection.
Read MoreThe test being developed could signal whether metastatic HPV-positive throat cancer treatment is working months earlier than standard imaging scans, allowing doctors to try alternatives sooner, initial results show.
Read MoreThe urine test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus and a panel of biomarkers validated by Birmingham University researchers to diagnose bladder cancer.
Read MoreA new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy.
Read MoreThe study aims to use a combination of blood-based testing, imaging, bone marrow sampling, and clinical questionnaires to improve our basic understanding of monoclonal gammopathy of undetermined significance, which precedes multiple myeloma.
Read MoreA study found a new urine screening test using a novel K17 cancer biomarker can detect new bladder cancer in patients with blood in the urine.
Read MoreResearchers have identified urine protein biomarkers of bladder cancer. ELISA validation was used to validate the top four biomarkers.
Read MoreA large-scale randomized trial of annual screening for ovarian cancer did not succeed in reducing deaths from the disease, despite one of the screening methods tested detecting cancers earlier.
Read MoreDecipher’s comprehensive portfolio of tests in urologic cancers leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making.
Read MoreThe grant will allow Qlucore to expand Qlucore Diagnostics software with a focus on RNA-profiling of glioma and acute leukemia.
Read More